Parenchymal central nervous system involvement in aggressive B-cell lymphoma: retrospective analysis of clinical and MRI features in a Chinese population

[1]  J. Abramson,et al.  Advances in risk assessment and prophylaxis for central nervous system relapse in diffuse large B-cell lymphoma , 2018, Haematologica.

[2]  R. MacCann,et al.  An Unusual Presentation of a Low Grade Follicular Lymphoma Masquerading as a Meningioma , 2018, Annals of Hematology & Oncology.

[3]  L. Sehn,et al.  Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma. , 2018, European journal of cancer.

[4]  J. Weichet,et al.  Secondary central nervous system lymphoma: spectrum of morphological MRI appearances , 2018, Neuropsychiatric disease and treatment.

[5]  C. Grommes,et al.  Updates on Primary Central Nervous System Lymphoma , 2018, Current Oncology Reports.

[6]  A. Salar,et al.  Guidelines for diagnosis, prevention and management of central nervous system involvement in diffuse large B-cell lymphoma patients by the Spanish Lymphoma Group (GELTAMO) , 2017, Haematologica.

[7]  R. Houot,et al.  Patterns of response and relapse in primary CNS lymphomas after first-line chemotherapy: imaging analysis of the ANOCEF-GOELAMS prospective randomized trial , 2016, Neuro-oncology.

[8]  J. Weichet,et al.  Central nervous system lymphoma: a morphological MRI study. , 2016, Neuro endocrinology letters.

[9]  Jing Zhang,et al.  Impact of rituximab on incidence of and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: a systematic review and meta-analysis , 2014, Leukemia & lymphoma.

[10]  C. Fletcher,et al.  Central nervous system involvement in diffuse large B-cell lymphoma: an analysis of risks and prevention strategies in the post-rituximab era , 2014, Leukemia & lymphoma.

[11]  B. Cheson,et al.  Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  S. Josephson,et al.  A systematic approach to the diagnosis of suspected central nervous system lymphoma. , 2013, JAMA neurology.

[13]  T. Siegal,et al.  CNS prophylaxis in diffuse large B-cell lymphoma: if, when, how and for whom? , 2012, Blood reviews.

[14]  G. Schulte-Altedorneburg,et al.  Current strategies in the diagnosis of diffuse large B‐cell lymphoma of the central nervous system , 2012, British journal of haematology.

[15]  Y. Oki,et al.  Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: analyses with competing risk regression model , 2011, Leukemia & lymphoma.

[16]  M. Mut,et al.  Parenchymal lymphoma of the brain on initial MR imaging: a comparative study between primary and secondary brain lymphoma. , 2011, European journal of radiology.

[17]  R. Gascoyne,et al.  Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  N. Schmitz,et al.  CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). , 2009, Blood.

[19]  M. Vaněčková,et al.  Concurrent occurrence of multiple sclerosis and primary CNS lymphoma: a case report. , 2008, Neuro endocrinology letters.

[20]  E. Neuwelt,et al.  Distinguishing primary central nervous system lymphoma from other central nervous system diseases: a neurosurgical perspective on diagnostic dilemmas and approaches. , 2006, Neurosurgical focus.

[21]  Y. Ishigatsubo,et al.  Secondary Central Nervous System Lymphoma , 2006, International journal of hematology.

[22]  J. Armitage,et al.  Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  H. Tilly,et al.  Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: A GELA study on 974 patients , 2000 .

[24]  H Fujita,et al.  Predictive Factors for Central Nervous System Involvement in Non-Hodgkin's Lymphoma: Significance of Very High Serum LDH Concentrations , 2000, Leukemia & lymphoma.

[25]  P. Mclaughlin,et al.  Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. , 1998, Blood.

[26]  H. Tilly,et al.  Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients. Groupe d'Etudes des Lymphomes de l'Adulte. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.